Two important trials--the MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD) and ANCHOR (Anti-VEGF Antibody Ranibizumab for the Treatment of Predominantly Classic Choroidal Neovascularization
in AMD)--showed the beneficial effect of Lucentis for neovascular AMD, regardless of lesion subtype.
MARINA (Minimally Classic/OccultTrial of the Anti-Vascular Endothelial Growth Factor Antibody Ranibizumab in the Treatment of Neovascular Endothelial Age-Related Macular Degeneration) and ANCHOR (Anti-VEGF antibody for the treatment of predominantly classic Choroidal Neovascularization
in Age-Related Macular Degeneration) evaluated drugs including Lucentis, for treatment of age-related and other forms of macular degeneration (AMD).
The MARINA study enrolled patients with occult and minimally classic choroidal neovascularization
(CNV), the form of CNV found in most patients with wet AMD, while the ANCHOR study enrolled patients with predominantly classic CNV.